NATCO Pharma Limited

As of June 30, 2026, NATCO Pharma Limited carries a market capitalization of 166.80B, placing it among publicly traded companies globally. Its enterprise value stands at 166.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NATCO Pharma Limited's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, NATCO Pharma Limited has 180.57M shares outstanding.

As of June 30, 2026, NATCO Pharma Limited trades at a trailing price-to-earnings ratio of 14.46.

As of June 30, 2026, NATCO Pharma Limited trades at an EV/EBITDA multiple of 15.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 166.80B versus a market cap of 166.80B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.96M in revenue per employee across its workforce of 5,007.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, NATCO Pharma Limited recorded 907.00M in income tax expense. That works out to an effective tax rate of 8.21, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.05B, leaving 11.44B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, NATCO Pharma Limited's stock has declined approximately 5.99% over the past 52 weeks. The 50-day moving average sits at 832.05, while the 200-day moving average is 925.79.

Over the twelve months ended June 30, 2026, NATCO Pharma Limited generated 34.85B in revenue and converted that into 11.44B in net income, yielding earnings per share of 63.92. EBITDA reached 10.52B, while operating income came in at 8.56B.

Over the twelve months ended June 30, 2026, NATCO Pharma Limited posted a gross margin of 82.64, reflecting its pricing power and cost economics. The operating margin of 24.56 and net profit margin of 32.84 provide insight into operational efficiency.

NATCO Pharma Limited's most recent stock split took place on October 1, 2026 with a 614:619 split ratio.